Markets Canaccord ups Acutus Medical to buy from hold; PT to $18 from $11 Canaccord Capital upgraded Acutus Medical (NASDAQ:AFIB) to “buy” from “hold” and raised its price target to $18 from $11, citing the company’s pre-announcement of second quarter results, which “illustrate early signs of... July 15, 2021